A small dose in time..

Good Clinical Practice Journal

Volumn 11, Issue 5, 2004, Pages 17-19

  Wilding, Ian ^a   Garner, Colin ^b  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b Xceleron Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; NEW DRUG;

ACCURACY; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER MODEL; COST BENEFIT ANALYSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NOTE; PREDICTION;

EID: 2342638913     PISSN: 13500961     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. G Lappin, RC Garner. 'Big physics, small doses: the use of AMS and PET in human microdosing of development drugs'. Nature Reviews: Drug Discovery, 2, pp233-240, March, 2003.
2. Tufts Center for the Study of Drug Development, News Release 13 March, 2003 (http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=29).
3. I Wilding. 'Injecting innovation into the drug development process'. Scrip Magazine, October, pp15-16, 2002.
4. JA Dimasi. 'Risks in new drug development: approval success rates for investigational drugs'. Clinical Pharmacology and Therapeutics, 69, pp297-307, 2001.
5. EMEA. 'Position Paper on the Nonclinical Safety Studies to Support Clinical Trials with a Single Microdose'. CPMP/SWP2599/02, 23 January 2003 (www.emea.eu.int/pdfs/human/swp/259902en/pdf).
6. IR Wilding, DV Prior. 'Remote controlled capsules in human drug absorption (HDA) studies'. Critical Reviews in Therapeutic Drug Carrier Systems, 20, 6, pp405-431, 2003.